NPS Pharmaceuticals, Inc.

331 articles about NPS Pharmaceuticals, Inc.

• NPS Pharmaceuticals, Inc. Announces Proposed Public Offering of 6,000,000 Shares of Its Common Stock

  5/21/2013

• NPS Pharmaceuticals, Inc. President and CEO Dr. Francois Nader Recognized as Regional Finalist for Ernst & Young LLP Entrepreneur of the Year® 2013

  5/16/2013

• NPS Pharmaceuticals, Inc. Recognized by National Organization for Rare Disorders for Gattex© as an Innovative Treatment for Patients With Short Bowel Syndrome

  5/15/2013

• NPS Pharmaceuticals, Inc. Reports First Quarter 2013 Financial Results

  5/9/2013

• NPS Pharmaceuticals, Inc. to Report First Quarter 2013 Financial Results

  5/1/2013

• NPS Pharmaceuticals, Inc. to Present at Needham Healthcare Conference

  4/22/2013

• NPS Pharmaceuticals, Inc. Buys Back $80 Million Worldwide Rights From Takeda Pharmaceutical Co. Ltd.

  3/19/2013

• NPS Pharmaceuticals, Inc. to Present at Barclays Capital Global Healthcare Conference

  3/5/2013

• NPS Pharmaceuticals, Inc. Reports 2012 Financial Results and 2013 Guidance

  2/22/2013

• NPS Pharmaceuticals, Inc. to Present at RBC Capital Markets Healthcare Conference

  2/20/2013

• NPS Pharmaceuticals, Inc. to Report 2012 Financial Results

  2/13/2013

• NPS Pharmaceuticals, Inc. to Present at Upcoming Conferences

  2/6/2013

• NPS Pharmaceuticals, Inc. Release: New Peer-Reviewed Publication Offers Guidance for Integrating Gattex® (Teduglutide [rDNA origin]) for Injection into Management of Short Bowel Syndrome

  1/30/2013

• NPS Pharmaceuticals, Inc. to Present at J.P. Morgan Healthcare Conference

  1/3/2013

• NPS Pharmaceuticals, Inc. to Host Conference Call to Discuss FDA Approval of Gattex® (teduglutide [rDNA Origin]) for Injection for the Treatment of Adult Short Bowel Syndrome

  1/2/2013

• NPS Pharmaceuticals, Inc. Signs Agreements With Leading Specialty Home Infusion Providers to Support Distribution and Home-based Clinical Care Services for Gattex®

  12/27/2012

• FDA Approves NPS Pharmaceuticals, Inc.'s Gattex to Treat Short Bowel Syndrome

  12/26/2012

• NPS Pharmaceuticals, Inc. Announces Publication of Pivotal Phase 3 Study of Gattex® (teduglutide) in Short Bowel Syndrome-Intestinal Failure Patients

  11/29/2012

• NPS Pharmaceuticals, Inc. Reports Third Quarter 2012 Financial Results and Reiterates Year-end Cash Guidance

  11/9/2012

• NPS Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences

  11/8/2012